These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 27813497)

  • 1. Serum APE1 as a predictive marker for platinum-based chemotherapy of non-small cell lung cancer patients.
    Zhang S; He L; Dai N; Guan W; Shan J; Yang X; Zhong Z; Qing Y; Jin F; Chen C; Yang Y; Wang H; Baugh L; Tell G; Wilson DM; Li M; Wang D
    Oncotarget; 2016 Nov; 7(47):77482-77494. PubMed ID: 27813497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
    Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer.
    Zhao W; Hu L; Xu J; Shen H; Hu Z; Ma H; Shu Y; Shao Y; Yin Y
    Cancer Chemother Pharmacol; 2013 May; 71(5):1287-95. PubMed ID: 23479135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients.
    Peng Y; Li Z; Zhang S; Xiong Y; Cun Y; Qian C; Li M; Ren T; Xia L; Cheng Y; Wang D
    Int J Cancer; 2014 Dec; 135(11):2687-96. PubMed ID: 24729390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum APE1 autoantibodies: a novel potential tumor marker and predictor of chemotherapeutic efficacy in non-small cell lung cancer.
    Dai N; Cao XJ; Li MX; Qing Y; Liao L; Lu XF; Zhang SH; Li Z; Yang YX; Wang D
    PLoS One; 2013; 8(3):e58001. PubMed ID: 23472128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reactive Oxygen Species Modulator 1 (Romo1) Predicts Poor Outcomes in Advanced Non-small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy.
    Lee SH; Choi SI; Lee JS; Kim CH; Jung WJ; Lee EJ; Min KH; Hur GY; Lee SH; Lee SY; Kim JH; Lee SY; Shin C; Shim JJ; Kang KH; In KH
    Cancer Res Treat; 2017 Jan; 49(1):141-149. PubMed ID: 27188201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. APE1 may influence CD4+ naïve T cells on recurrence free survival in early stage NSCLC.
    Li Y; Zhao X; Xiao H; Yang B; Liu J; Rao W; Dai X; Li M; Dai N; Yang Y; Wang D
    BMC Cancer; 2021 Mar; 21(1):233. PubMed ID: 33676448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
    Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
    Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy.
    Sone K; Oguri T; Nakao M; Kagawa Y; Kurowaka R; Furuta H; Fukuda S; Uemura T; Takakuwa O; Kanemitsu Y; Ohkubo H; Takemura M; Maeno K; Ito Y; Sato H; Muramatsu H; Niimi A
    Anticancer Res; 2017 Feb; 37(2):935-939. PubMed ID: 28179355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells.
    Wang D; Xiang DB; Yang XQ; Chen LS; Li MX; Zhong ZY; Zhang YS
    Lung Cancer; 2009 Dec; 66(3):298-304. PubMed ID: 19324449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic and prognostic value of serum thioredoxin and DJ-1 in non-small cell lung carcinoma patients.
    Fan J; Yu H; Lv Y; Yin L
    Tumour Biol; 2016 Feb; 37(2):1949-58. PubMed ID: 26334622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apurinic/Apyrimidinic Endonuclease 1/Redox Factor-1 Could Serve as a Potential Serological Biomarker for the Diagnosis and Prognosis of Oral Squamous Cell Carcinoma.
    Xie J; Li Y; Kong J; Li C
    J Oral Maxillofac Surg; 2019 Apr; 77(4):859-866. PubMed ID: 30611690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Impact of DNA Repair Protein Expression in Non-Small Cell Lung Cancers Treated with Platinum-Based Chemotherapy and Subsequent Curative Lung Resection.
    Shin J; Lee KS; Yoh KA; Cho HJ; Choi MK; Kim SH; Kim YJ; Chung JH; Cho S; Kim K; Jheon S; Yoon HI; Lee JH; Lee CT; Lee JS
    Oncology; 2018; 95(1):20-30. PubMed ID: 29694959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutrophil-to-lymphocyte ratio is superior to platelet-to-lymphocyte ratio as a prognostic predictor in advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy.
    Guo D; Li M; Chen D; Jing W; Zhu H; Fu L; Kong L; Yue J; Yu J
    Future Oncol; 2019 Feb; 15(6):625-635. PubMed ID: 30430864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of serum carcinoembryonic antigen (CEA) in evaluating response to chemotherapy in patients with advanced non small-cell lung cancer: a prospective cohort study.
    Arrieta O; Villarreal-Garza C; Martínez-Barrera L; Morales M; Dorantes-Gallareta Y; Peña-Curiel O; Contreras-Reyes S; Macedo-Pérez EO; Alatorre-Alexander J
    BMC Cancer; 2013 May; 13():254. PubMed ID: 23697613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum ferritin is elevated in advanced non-small cell lung cancer patients and is associated with efficacy of platinum-based chemotherapy.
    Shi HB; Li XD; Jiang JT; Zhao WQ; Ji M; Wu CP
    J Cancer Res Ther; 2014; 10(3):681-5. PubMed ID: 25313760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin D deficiency is associated with a poor prognosis in advanced non-small cell lung cancer patients treated with platinum-based first-line chemotherapy.
    Ma K; Xu W; Wang C; Li B; Su K; Li W
    Cancer Biomark; 2017; 18(3):297-303. PubMed ID: 27983538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of serum carcinoembryonic antigen in predicting responses to chemotherapy and survival in patients with non-small cell lung cancer.
    Liu H; Gu X; Lv T; Wu Y; Xiao Y; Yuan D; Li Y; Song Y
    J Cancer Res Ther; 2014; 10(2):239-43. PubMed ID: 25022372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heat shock protein 70 as a predictive marker for platinum-based adjuvant chemotherapy in patients with resected non-small cell lung cancer.
    Park TS; Kim HR; Koh JS; Jang SH; Hwang YI; Yoon HI; Chung JH; Kim CH; Kim SS; Kim WS; Jo J; Lee JC; Choi CM
    Lung Cancer; 2014 Nov; 86(2):262-7. PubMed ID: 25261232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy.
    Vassalou H; Stathopoulos E; Fiolitaki G; Koutsopoulos A; Voutsina A; Georgoulias V; Mavroudis D
    Lung Cancer; 2013 Nov; 82(2):324-9. PubMed ID: 23993732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.